- Home
- IMCR vs GOF Comparison
IMCR vs GOF Comparison
Compare IMCR & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- GOF
- Stock Information
- Founded
- IMCR 2008
- GOF 2006
- Country
- IMCR United Kingdom
- GOF United States
- Employees
- IMCR N/A
- GOF N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- GOF Finance/Investors Services
- Sector
- IMCR Health Care
- GOF Finance
- Exchange
- IMCR Nasdaq
- GOF Nasdaq
- Market Cap
- IMCR 1.5B
- GOF 2.4B
- IPO Year
- IMCR 2021
- GOF N/A
- Fundamental
- Price
- IMCR $32.80
- GOF $14.92
- Analyst Decision
- IMCR Buy
- GOF
- Analyst Count
- IMCR 10
- GOF 0
- Target Price
- IMCR $58.13
- GOF N/A
- AVG Volume (30 Days)
- IMCR 444.9K
- GOF 789.2K
- Earning Date
- IMCR 08-07-2025
- GOF 01-01-0001
- Dividend Yield
- IMCR N/A
- GOF 15.42%
- EPS Growth
- IMCR N/A
- GOF N/A
- EPS
- IMCR N/A
- GOF N/A
- Revenue
- IMCR $333,581,000.00
- GOF N/A
- Revenue This Year
- IMCR $26.82
- GOF N/A
- Revenue Next Year
- IMCR $8.15
- GOF N/A
- P/E Ratio
- IMCR N/A
- GOF N/A
- Revenue Growth
- IMCR 25.75
- GOF N/A
- 52 Week Low
- IMCR $23.15
- GOF $10.96
- 52 Week High
- IMCR $41.54
- GOF $16.76
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- GOF 61.54
- Support Level
- IMCR $30.76
- GOF $14.76
- Resistance Level
- IMCR $33.95
- GOF $14.95
- Average True Range (ATR)
- IMCR 1.39
- GOF 0.12
- MACD
- IMCR -0.15
- GOF 0.03
- Stochastic Oscillator
- IMCR 43.05
- GOF 100.00
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.